I-Mab stock (KYG476301028): Chinese biotech focuses on pipeline after Nasdaq delisting and business update

I-Mab has withdrawn from Nasdaq and is refocusing its immuno-oncology pipeline after a strategic business update and changes to its partnership with AbbVie. What this means for the biotech’s future prospects and risks.

I-Mab, a clinical-stage biopharma focused on immuno-oncology, has reshaped its strategy following its delisting from Nasdaq and a broader business update that included changes to a key partnership and pipeline priorities. The company now positions itself more as a China-focused innovation engine with selective global ambitions, according to recent company disclosures and filings, including its 2023 annual report published in April 2024 and subsequent updates on its investor relations website I-Mab IR as of 04/22/2024.

As of: 16.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: I-Mab
• Sector/industry: Biotechnology, immuno-oncology
• Headquarters/country: Shanghai, China
• Core markets: China and selected global oncology markets
• Key revenue drivers: R&D collaboration payments, potential future oncology product sales
• Home exchange/listing venue: Previously Nasdaq; now primarily traded over-the-counter in the US according to market data portals
• Trading currency: Historically USD for US-listed shares

I-Mab: core business model

I-Mab describes itself as a clinical-stage biopharmaceutical company focusing on the discovery, development and potential commercialization of innovative biologics in immuno-oncology and autoimmune diseases. The group’s strategy is built around discovering novel antibody-based therapies, rapidly advancing them through clinical trials in China, and then seeking partners or optional expansion into global markets, according to the company’s corporate profile and filings I-Mab corporate profile as of 03/15/2024.

The company’s origins lie in bridging Chinese and international biotech R&D, combining in-house discovery capabilities with in-licensing of promising assets. Its platform emphasizes targets in immune modulation and tumor microenvironment, areas considered key to advancing cancer immunotherapy. Over the past years I-Mab has invested heavily in research centers, clinical development expertise and regulatory capabilities in China in order to move assets from preclinical proof-of-concept into mid- to late-stage trials in solid tumors and hematologic cancers, as outlined in its annual report for the year ended December 31, 2023, released in April 2024 I-Mab annual report as of 04/22/2024.

A central element of the business model has been to partner selected assets with global pharmaceutical companies in order to access larger development budgets and commercialization networks outside China. Historically, this included collaborations such as the one with AbbVie on the CD47-targeting antibody lemzoparlimab. Although this particular partnership was later restructured and parts unwound, it illustrates the company’s approach: advance early science to a de-risked stage in China, then seek value-sharing arrangements for worldwide development while retaining certain rights in its home market, according to partnership disclosures reported in prior company releases and covered by international business media Reuters as of 02/21/2020.

Following a challenging period for biotech funding and changes in its partnership landscape, I-Mab has moved toward a leaner operating model. Company statements in 2023 and 2024 emphasized cost control, portfolio prioritization and a focus on assets with clearer clinical differentiation. This includes streamlining early-stage programs and concentrating resources on candidates with more advanced data packages or clearer regulatory paths in China’s evolving oncology market, based on strategic updates disclosed in earnings and corporate presentations I-Mab news releases as of 11/30/2023.

Main revenue and product drivers for I-Mab

Historically, I-Mab’s revenue base has been dominated by milestone and collaboration payments rather than large-scale product sales. In its annual report for 2023, the company noted that revenue for the year ended December 31, 2023 mainly reflected recognized income from existing licensing and collaboration agreements, while it had not yet fully transitioned to a commercial-stage revenue profile, according to the filing dated April 22, 2024 I-Mab annual report as of 04/22/2024.

The most visible potential value drivers are its clinical-stage oncology assets. Among them are monoclonal antibodies and bispecific antibodies designed to enhance anti-tumor immune responses. The pipeline has included, for example, CD47 and other immune checkpoint-related programs, as well as targets addressing solid tumors and hematologic malignancies. The commercial logic is that, should one or more of these candidates achieve regulatory approval in China or other jurisdictions, I-Mab could earn product sales, royalties or additional milestone payments, depending on ownership and partnership structures detailed in its collaboration agreements.

Development timelines and regulatory outcomes represent the key uncertainties. I-Mab has reported progress in certain Phase 1 and Phase 2 trials, while also adjusting or discontinuing some programs in response to clinical data, competitive developments and partner decisions. This dynamic is common in oncology biotech, where attrition rates are high and even promising mechanisms may face hurdles such as safety concerns, limited efficacy signals or crowded competitive spaces, as reflected in broader industry assessments by sector analysts and specialized media Fierce Biotech as of 09/05/2024.

Over the medium term, the company’s ability to convert its pipeline into recurring cash flows is likely to depend on multiple factors: successful completion of pivotal trials in China, the pace of regulatory review by the National Medical Products Administration, and reimbursement decisions that affect pricing and patient access. For international markets, additional elements come into play, such as the willingness of global pharma partners to commit to late-stage development, the competitive landscape in specific indications, and evolving attitudes of regulators like the US Food and Drug Administration and the European Medicines Agency toward novel immuno-oncology mechanisms.

Why I-Mab matters for US investors

Even though I-Mab has withdrawn its primary listing from Nasdaq and transitioned to over-the-counter trading in the United States, the stock remains relevant for certain US-based investors who follow emerging market biotech and China’s oncology innovation ecosystem. The company’s earlier presence on a major US exchange helped build name recognition and brought its pipeline onto the radar of global healthcare funds, according to trading and listing updates cited by financial news outlets in 2023 and 2024 Nasdaq data as of 02/29/2024.

For investors in the US, I-Mab can be viewed within a broader group of China-based biotechs that seek to leverage domestic clinical infrastructure while accessing international capital and partnering opportunities. These companies often face a different risk profile compared with US domestic biotech peers. Alongside the usual drug development and funding risks, they must navigate cross-border regulatory considerations, changes in geopolitical sentiment and evolving rules around foreign listings and data sharing. For I-Mab, the shift away from a primary US listing has highlighted these structural factors while also reducing liquidity and visibility relative to its peak Nasdaq trading period.

At the same time, US investors interested in oncology innovation sometimes monitor China-origin assets because they may address large global indications or introduce differentiated targets. In this context, I-Mab’s portfolio may still be of interest as a case study of how Chinese discovery platforms evolve and how global partnerships are structured and restructured over time. The company’s collaboration history, cost-cutting measures and pipeline reprioritizations provide data points on how cross-border biotech models adapt when markets turn more demanding and capital becomes more selective, a trend often noted in sector overviews by research firms covering global biotech funding cycles S&P Global as of 01/18/2024.

Conclusion

I-Mab stands at a transitional point in its corporate story. The move away from a primary Nasdaq listing, portfolio reprioritizations and changes in key partnerships underline both the headwinds facing many development-stage biotechs and the company’s attempts to preserve capital and focus on the most promising oncology assets. For investors, this results in a mixed picture: a pipeline with scientific ambition, anchored in China’s growing oncology market, but paired with uncertainties around funding, execution, regulatory milestones and cross-border dynamics. How effectively management implements its streamlined strategy, secures potential partners and advances pivotal trials will likely determine whether the company can convert its scientific platform into lasting commercial relevance in China and, selectively, in global markets.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.